Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Completed · Phase 1

Conditions studied: Rectal Cancer

In brief

The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). Additionally, the investigators want to determine if it is possible to predict how well tumor(s) might respond to treatment with \[18F\]-FLT PET imaging.

Key facts

Study ID

NCT01207895

Run by

Vanderbilt-Ingram Cancer Center

People needed

5

Starts

2010-03-01

Expected to finish

2013-07-01

Last updated by the study team

2017-02-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with known rectal cancer.
• Subjects must have signed an approved consent form.
• Subjects must be 18 years of age or older.

You may not qualify if…

• Children less than 18 are excluded.
• Pregnant women and women who are breast feeding will be excluded from this study. A serum beta HCG will also be performed for each pre-menopausal female subject.
• Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study

Where it is running

• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.